Thrivent Financial for Lutherans Has $6.41 Million Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Thrivent Financial for Lutherans increased its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 86.8% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 46,577 shares of the company’s stock after acquiring an additional 21,641 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Neurocrine Biosciences were worth $6,412,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of NBIX. Commonwealth Equity Services LLC grew its stake in shares of Neurocrine Biosciences by 0.6% in the 1st quarter. Commonwealth Equity Services LLC now owns 13,941 shares of the company’s stock valued at $1,923,000 after buying an additional 84 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd grew its stake in Neurocrine Biosciences by 0.8% in the second quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 11,436 shares of the company’s stock valued at $1,574,000 after acquiring an additional 90 shares during the period. Fifth Third Bancorp grew its stake in Neurocrine Biosciences by 14.7% in the second quarter. Fifth Third Bancorp now owns 716 shares of the company’s stock valued at $99,000 after acquiring an additional 92 shares during the period. Total Clarity Wealth Management Inc. raised its position in shares of Neurocrine Biosciences by 4.3% during the second quarter. Total Clarity Wealth Management Inc. now owns 2,433 shares of the company’s stock worth $335,000 after purchasing an additional 100 shares during the period. Finally, Park Avenue Securities LLC lifted its holdings in shares of Neurocrine Biosciences by 1.1% in the 1st quarter. Park Avenue Securities LLC now owns 9,570 shares of the company’s stock worth $1,320,000 after purchasing an additional 101 shares in the last quarter. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Gary A. Lyons sold 930 shares of the firm’s stock in a transaction that occurred on Tuesday, July 16th. The shares were sold at an average price of $150.03, for a total value of $139,527.90. Following the completion of the transaction, the director now directly owns 119,047 shares in the company, valued at $17,860,621.41. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other Neurocrine Biosciences news, Director Gary A. Lyons sold 930 shares of the stock in a transaction that occurred on Tuesday, July 16th. The shares were sold at an average price of $150.03, for a total value of $139,527.90. Following the sale, the director now directly owns 119,047 shares in the company, valued at approximately $17,860,621.41. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Ingrid Delaet sold 273 shares of the business’s stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $147.70, for a total transaction of $40,322.10. Following the transaction, the insider now owns 6,607 shares of the company’s stock, valued at $975,853.90. The disclosure for this sale can be found here. Insiders have sold a total of 71,798 shares of company stock worth $10,676,096 over the last ninety days. Company insiders own 4.30% of the company’s stock.

Analyst Upgrades and Downgrades

NBIX has been the topic of several research reports. Royal Bank of Canada lowered their price objective on shares of Neurocrine Biosciences from $143.00 to $136.00 and set a “sector perform” rating on the stock in a report on Thursday, August 29th. HC Wainwright restated a “buy” rating and issued a $190.00 target price on shares of Neurocrine Biosciences in a report on Thursday, August 29th. Oppenheimer upped their price target on Neurocrine Biosciences from $216.00 to $219.00 and gave the stock an “outperform” rating in a report on Friday, August 2nd. Morgan Stanley raised their price objective on Neurocrine Biosciences from $160.00 to $170.00 and gave the company an “overweight” rating in a research note on Friday, July 12th. Finally, Jefferies Financial Group lifted their price objective on shares of Neurocrine Biosciences from $177.00 to $189.00 and gave the stock a “buy” rating in a report on Monday, August 19th. Five equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $162.20.

Neurocrine Biosciences Stock Up 1.2 %

NBIX opened at $115.93 on Friday. The firm has a 50-day moving average price of $136.67 and a 200-day moving average price of $137.77. Neurocrine Biosciences, Inc. has a twelve month low of $103.63 and a twelve month high of $157.98. The company has a market capitalization of $11.67 billion, a price-to-earnings ratio of 31.94 and a beta of 0.37.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings data on Thursday, August 1st. The company reported $0.63 earnings per share for the quarter, missing analysts’ consensus estimates of $1.15 by ($0.52). The business had revenue of $590.20 million during the quarter, compared to analysts’ expectations of $545.98 million. Neurocrine Biosciences had a net margin of 16.00% and a return on equity of 14.86%. The firm’s quarterly revenue was up 30.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.95 earnings per share. On average, sell-side analysts expect that Neurocrine Biosciences, Inc. will post 4.19 earnings per share for the current fiscal year.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.